For adults with Parkinson’s disease

For adults with Parkinson’s disease (PD)

From lunch to leash to lake

Stay in step with your day with CREXONT: More “Good On” time* with less frequent dosing compared with immediate-release carbidopa/levodopa (IR CD/LD)

*“Good On” time is defined as “On” time without troublesome dyskinesia.

As seen in a clinical study.

Take your next step

DAVID,
a real person with Parkinson’s disease

More “Good On” time* with less frequent dosing compared with IR CD/LD

How CREXONT works

Designed to gradually release levodopa

CREXONT is designed to gradually release levodopa in the part of the gut where it is best absorbed, although the exact site and duration of absorption is unknown

More “Good On” time*

People who took CREXONT an average of 3 times a day achieved 30 minutes more “Good On” time per day than those taking IR CD/LD an average of 5 times a day

Personalized dosing

CREXONT dosing starts at 3 times per day for most patients, though dosing may start at 2 to 3 times per day. After 1 to 3 days, your doctor may adjust your dose or frequency. CREXONT may be dosed up to 4 times a day

How CREXONT works

Are you optimizing your “Good On” time* with your current Parkinson’s disease treatment?

IR CD/LD has been the standard of care for treating PD for many years—it’s designed to work quickly but may wear off quickly too.

About “Good On” time

Are you ready to ask your doctor about CREXONT?

Your “On” time matters—talk with your doctor today to see if you can get more “Good On” time* with CREXONT

Support & resources

Footnotes

*“Good On” time is defined as “On” time without troublesome dyskinesia.

As seen in a clinical study.

Change in “Good On” time was measured by comparing values at the end of study to baseline; P=0.019 vs IR CD/LD.

Indication & Important Safety Information

INDICATION

CREXONT® (carbidopa and levodopa) extended-release capsules is a prescription medication for the treatment of Parkinson’s disease, Parkinson’s disease caused by infection or inflammation of the brain, or Parkinson’s disease-like symptoms that may result from carbon monoxide or manganese poisoning in adults.

IMPORTANT SAFETY INFORMATION

Do not take CREXONT with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors.

Do not take CREXONT with other carbidopa-levodopa preparations without consulting your healthcare provider.

CREXONT may cause falling asleep during activities of daily living, somnolence, or dizziness. Avoid activities that require alertness such as driving and operating machinery until you know how CREXONT affects you.

The most common side effects that may occur with CREXONT are nausea and anxiety.

It is important to avoid sudden discontinuation or rapid dose reduction of CREXONT. If you are discontinuing CREXONT, work with your healthcare provider to taper the dose over time to reduce the risk of fever or confusion.

You may take CREXONT with or without food, but taking it with food may decrease or delay its effect. Consider taking the first dose of the day about 1 to 2 hours before eating.

Swallow CREXONT whole. Do not chew, divide, or crush the capsules.

Do not take CREXONT with alcohol.

Tell your healthcare provider if you:

  • Have any heart conditions, especially if you have had a heart attack or irregular heartbeats
  • Experience hallucinations or abnormal thoughts and behaviors
  • Have an inability to control urges to gamble, have increased sexual urges, or experience other intense urges
  • Have thoughts of suicide or have attempted suicide
  • Have abnormal involuntary movements that appear or get worse during treatment
  • Have ever had a peptic ulcer or glaucoma
  • Become or intend to become pregnant. Based on animal data, CREXONT may cause fetal harm
  • Are breastfeeding during therapy

INDICATION

CREXONT® (carbidopa and levodopa) extended-release capsules is a prescription medication for the treatment of Parkinson’s disease, Parkinson’s disease caused by infection or inflammation of the brain, or Parkinson’s disease-like symptoms that may result from carbon monoxide or manganese poisoning in adults.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Specialty, a division of Amneal Pharmaceuticals, LLC at 1-877-835-5472 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please read the full Prescribing Information. For more information talk to your healthcare provider.

Indication & Important Safety Information

INDICATION

CREXONT® (carbidopa and levodopa) extended-release capsules is a prescription medication for the treatment of Parkinson’s disease, Parkinson’s disease caused by infection or inflammation of the brain, or Parkinson’s disease-like symptoms that may result from carbon monoxide or manganese poisoning in adults.

IMPORTANT SAFETY INFORMATION

Do not take CREXONT with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors.

Do not take CREXONT with other carbidopa-levodopa preparations without consulting your healthcare provider.

CREXONT may cause falling asleep during activities of daily living, somnolence, or dizziness. Avoid activities that require alertness such as driving and operating machinery until you know how CREXONT affects you.

The most common side effects that may occur with CREXONT are nausea and anxiety.

It is important to avoid sudden discontinuation or rapid dose reduction of CREXONT. If you are discontinuing CREXONT, work with your healthcare provider to taper the dose over time to reduce the risk of fever or confusion.

You may take CREXONT with or without food, but taking it with food may decrease or delay its effect. Consider taking the first dose of the day about 1 to 2 hours before eating.

Swallow CREXONT whole. Do not chew, divide, or crush the capsules.

Do not take CREXONT with alcohol.

Tell your healthcare provider if you:

  • Have any heart conditions, especially if you have had a heart attack or irregular heartbeats
  • Experience hallucinations or abnormal thoughts and behaviors
  • Have an inability to control urges to gamble, have increased sexual urges, or experience other intense urges
  • Have thoughts of suicide or have attempted suicide
  • Have abnormal involuntary movements that appear or get worse during treatment
  • Have ever had a peptic ulcer or glaucoma
  • Become or intend to become pregnant. Based on animal data, CREXONT may cause fetal harm
  • Are breastfeeding during therapy

INDICATION

CREXONT® (carbidopa and levodopa) extended-release capsules is a prescription medication for the treatment of Parkinson’s disease, Parkinson’s disease caused by infection or inflammation of the brain, or Parkinson’s disease-like symptoms that may result from carbon monoxide or manganese poisoning in adults.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Specialty, a division of Amneal Pharmaceuticals, LLC at 1-877-835-5472 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please read the full Prescribing Information. For more information talk to your healthcare provider.